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Abstract
Rho family GTP-binding proteins have been demonstrated to play a role in the regulation of phospholipase D (PLD)
activity. In the present study, we examined the role of Rho proteins in PLD activation in differentiated HL-60 cells using C3
exoenzyme from Clostridium botulinum, which ADP-ribosylates and inactivates Rho proteins. Introduction of C3 exoenzyme
into differentiated HL-60 cells by electroporation resulted in complete inhibition of PLD activity stimulated by formyl
methionine-leucine-phenylalanine (fMLP) and ATP, two receptor agonists. Phorbol myristate acetate-induced PLD
activation was also inhibited in C3 exoenzyme-treated cells, but the inhibition was only partial. GTPQS-dependent activation
of PLD, measured in the absence or presence of ATP in permeabilized cells, was also partially affected by C3 exoenzyme
treatment. Thus, these results indicate that Rho proteins play a key role in receptor-mediated PLD regulation in
differentiated HL-60 cells, but play a partial role in the in vivo action of PMA and in vitro action of GTPQS on PLD. ATP
produced a significant enhancement of the in vitro effect of GTPQS on PLD activity, but the effect of ATP was not altered by
inhibitors of serine/threonine and tyrosine kinases. However, it was markedly reduced by neomycin and accompanied by an
increase in phosphatidylinositol 4,5-bisphosphate (PtdInsP2) synthesis. These data indicate that in permeabilized HL-60 cells,
the stimulatory effect of ATP on PLD does not involve protein phosphorylation but is due to an increase in
PtdInsP2. ß 1998 Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Phospholipase D (PLD), which catalyzes the hy-
drolysis of phosphatidylcholine to choline and phos-
phatidic acid, has been implicated in signal transduc-
tion in a variety of cell types and in the regulation of
several cellular functions [1]. PLD is activated by
many extracellular signals and multiple factors are
involved in its cellular regulation [2].
Activation of membrane-associated PLD by the
non-hydrolyzable guanine nucleotide, guanosine
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phospholipase D; PMA, 4L-phorbol 12-myristate 13-acetate;
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5P-O-(3-thiotriphosphate) (GTPQS) has been ob-
served in reconstitution experiments when cytosol is
present in the reaction mixture [3,4]. Similar ¢ndings
have been obtained in permeabilized cells in which
the loss of cytosolic components resulted in the re-
duction of GTPQS-dependent PLD activity [5,6]. Two
kinds of small GTP-binding proteins, members of the
ADP-ribosylation factor (Arf) and Rho families of
proteins, have been identi¢ed as regulatory factors
for PLD activity [7^11]. Arf, ¢rst identi¢ed as a co-
factor necessary for the ADP-ribosylation of the
K-subunit of the heterotrimeric G protein Gs by chol-
era toxin [12,13], has been implicated in vesicular
transport in the Golgi [14]. It was later described
as an activator of PLD partially puri¢ed from several
cell types and has now been shown to activate ho-
mogeneous preparations of certain PLD isozymes
(for references, see [2]). The presence of PtdInsP2 is
essential for the detection of Arf-regulated PLD ac-
tivity in vitro [7].
Rho proteins have been involved in the regulation
of the assembly of focal adhesion complexes and
actin stress ¢bers [15,16]. Evidence for involvement
of Rho family proteins, especially RhoA, in PLD
activation comes from the demonstration that Rho
GDI, a Rho speci¢c GDP dissociation inhibitor, in-
hibits activation of PLD by GTPQS [9,10,17,18]. Fur-
thermore, several toxins a¡ecting Rho proteins have
been useful tools for researching Rho-mediated PLD
regulation [19^22]. Clostridium botulinum C3 exoen-
zyme which speci¢cally ADP-ribosylates RhoA, B
and C proteins and prevents their interaction with
downstream targets [23], has been shown to inhibit
agonist-induced PLD activation in several cells
[20,21,24]. However, it has also been reported to be
ine¡ective in inhibiting GTPQS stimulation of PLD in
neutrophils and liver plasma membranes [10,18].
Although the involvement of Rho and Arf family
proteins in GTPQS-dependent activation of PLD has
been extensively studied in vitro, their involvement in
receptor-mediated PLD responses has been less in-
vestigated [22,25^27]. In HL-60 cells di¡erentiated
along the granulocyte pathway, receptor-mediated
activation of PLD by the chemotactic peptide, for-
myl methionine-leucine-phenylalanine (fLMP) and
by ATP, which binds to P2-purinoceptors, has been
demonstrated [28], in agreement with the present
¢ndings. Evidence has also been provided that
ARF and RhoA can stimulate PLD activity in the
presence of GTPQS in in vitro preparations from
these cells [7^9, 17]. The present work was performed
to identify the physiological contribution of Rho
proteins to PLD activation by investigating the e¡ect
of C3 exoenzyme on receptor-mediated regulation of
PLD in di¡erentiated HL-60 cells. The results dem-
onstrate that Rho proteins play a major role in
fMLP- and ATP-stimulated PLD activation in intact
HL-60 cells. On the other hand, C3 exoenzyme had
only a partial e¡ect on phorbol ester-induced PLD
activation in the intact cell and on GTPQS-dependent
activation of PLD in the permeabilized cells indicat-
ing the involvement of other mechanisms. Our results
also show an important role for PtdInsP2 synthesis
and a lack of a role for protein phosphorylation in
the enhancement by ATP of the stimulation of PLD
by GTPQS in vitro.
2. Experimental procedures
2.1. Materials
HL-60 human promyelocytic leukemic cell line was
from American Type Culture Collection (Rockville,
MD). RPMI 1640, and M199 media and fetal bovine
serum came from Irvine Scienti¢c (Santa Ana, CA).
Cytochalasin B, formyl-Met-Leu-Phe (fMLP),
4L-phorbol 12-myristate 13-acetate (PMA), dibutyryl
cyclic AMP (Bu2cAMP), inositol phospholipid
standards and L-escin were obtained from Sigma.
[3H]Myristic acid and myo-[3H]inositol were from
Du Pont-NEN. Silica-gel plates were purchased
from Whatman. 1,2-Dioleoyl-sn-glycero-3-phospho-
butanol (PtdBuOH) was from Avanti Polar Lipids
(Birmingham, AL). C. botulinum C3 exoenzyme
was from List Biological Laboratories (Campbell,
CA).
2.2. Cell culture and cell labeling
HL-60 cells were grown in RPMI 1640 medium
supplemented with 10% heat-inactivated fetal bovine
serum (FBS), 100 units/ml penicillin and 100 Wg/ml
streptomycin. Cells were grown at a density of 0.3^
2.0U106 cells/ml in a humidi¢ed atmosphere contain-
ing 5% CO2 at 37‡C. To induce di¡erentiation, the
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cells (1.0U106/ml) were incubated in RPMI 1640 me-
dium supplemented with 1% FBS, 100 units/ml pen-
icillin, 100 Wg/ml streptomycin and 500 WM Bu2-
cAMP for 3 days. [3H]Myristic acid (1 WCi/ml) was
added 18 h before the end of cell di¡erentiation.
For electroporation, di¡erentiated HL-60 cells
were harvested, washed once with 125 mM NaCl,
5 mM KC1, 1 mM MgCl2, 25 mM HEPES, 5 mM
glucose and 1 mg/ml BSA, pH 7.4 (bu¡er A), then
with 120 mM potassium glutamate, 20 mM potassi-
um acetate, 20 mM HEPES, 1 mM EGTA, 5 mM
glucose and 1 mg/ml BSA, pH 7.4 (bu¡er B) and
resuspended in this bu¡er at 1.0U107 cells/ml. Ali-
quots (0.8 ml) of cells were transferred into Bio-Rad
pulser cuvettes and permeabilized at room temper-
ature using one discharge of 250 V from a 960 WF
capacitor. After 10 min the cells were transferred to
RPMI 1640 medium containing 5% FBS and
[3H]myristic acid (1 WCi/ml) for 18^20 h before
PLD activity determination. Cell viability was esti-
mated by trypan blue exclusion. Cell survival after
electroporation was usually reduced (about 40^60%).
However, no signi¢cant di¡erences were observed
between viable cells electroporated in the presence
or absence of C3 exoenzyme.
2.3. Determination of PLD activity
Labeled HL-60 cells were harvested, washed with
bu¡er A containing 1 mM CaCl2, resuspended and
incubated in this bu¡er at 37‡C. The incubation vol-
ume was 200 Wl and contained 2.0U106 cells. The
cells were incubated with 0.5% butanol for 5 min
at 37‡C, then stimulated with fMLP, ATP or
PMA. Cytochalasin B (5 WM) was present during
the incubation when cells were stimulated by fMLP
and ATP.
For studies with permeabilized cells, labeled HL-
60 cells were harvested, washed once with bu¡er A,
then with bu¡er B containing 3 mM MgCl2, 1 WM
free Ca2, and resuspended in this bu¡er at 37‡C.
The incubation volume was 200 Wl and contained
3.0U106 cells, 40 Wg/ml L-escin and 0.5% butanol.
Reactions were stopped after the appropriate in-
cubation time by the addition of 750 Wl chloroform/
methanol/HC1 12 N (100:200:1, v/v). Cellular lipids
were extracted according to the method of Bligh and
Dyer [29]. The chloroform phase was dried and
dissolved in 20 Wl chloroform. These samples were
spotted on silica gel plates. The plates were devel-
oped using the upper phase of a mixture consisting
of ethylacetate/trimethylpentane/acetic acid/water
(13:2:3:10, v/v) for the separation of PtdBuOH.
The plates were stained with iodine vapor to locate
the standard PtdBuOH and scraped. The radioactiv-
ity associated with PtdBuOH was quanti¢ed by
liquid scintillation and expressed as a percentage of
the total radioactivity in the phospholipids (about
70 000 cpm).
2.4. ADP-ribosylation by C3 exoenzyme
HL-60 cells were pelleted by centrifugation,
washed in ice-cold bu¡er containing 50 mM HEPES,
1 mM EGTA and 1 mM EDTA, pH 7.4 and soni-
cated for 10 s. Cell lysate was incubated in the pres-
ence of 500 ng of C. botulinum C3 exoenzyme,
[32P]NAD (1 WCi, 350 Ci/mmol, ICN), 10 mM di-
thiothreitol, 5 mM MgCl2, 1 mM EDTA, 10 mM
thymidine, 1 mM ATP, 100 WM GTP and 2 WM
NAD at 30‡C for 1 h. The reaction was stopped
by adding ice-cold acetone. Precipitates were ana-
lyzed by SDS-PAGE and autoradiography.
2.5. Determination of inositol phospholipid levels
HL-60 cells were di¡erentiated in M199 medium
supplemented with 100 units/ml penicillin, 100 Wg/ml
streptomycin, 5 Wg/ml insulin, 5 Wg/ml transferrin,
5 ng/ml sodium selenite, 4 WM glutamine, 1.75 mg/
ml BSA and 500 WM bu2cAMP for 3 days. myo-
[3H]Inositol (2 WCi/ml) was added to the medium
during this period. Di¡erentiated HL-60 cells were
harvested, washed once with bu¡er A, then with buf-
fer B containing 3 mM MgCl2 and 1 WM free Ca2,
and resuspended in this bu¡er at 37‡C. Cells were
incubated in the presence of 40 Wg L-escin, with or
without GTPQS or ATP for 20 min, as described in
the ¢gures. The reaction was stopped by addition of
chloroform/methanol/12 M HC1 (100:200:1, v/v).
[3H]Inositol phospholipids were separated on oxa-
late-impregnated silica gel plates. The plates were
developed using chloroform/methanol/acetone/acetic
acid/water (120:39:45:36:24, v/v). The plates were
stained with iodine vapor to locate the standard
phosphatidylinositol (PtdIns), phosphatidylinositol
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4-monophosphate (PtdInsP) and phosphatidylinosi-
tol 4,5-bisphosphate (PtdInsP2) and then scraped.
The radioactivity associated with each phospholipid
was quanti¢ed by liquid scintillation.
3. Results
PLD activation by the two receptor agonists, ATP
and fMLP, can be observed in [3H]myristic acid-la-
beled HL-60 cells after 3 days of bu2cAMP-induced
di¡erentiation. PMA, a PKC activator, is also
known to activate PLD in various cell types includ-
ing HL-60 cells. To determine the role of Rho pro-
teins in these responses, we introduced C3 exoen-
zyme from C. botulinum into di¡erentiated HL-60
cells by electroporation and examined the PLD re-
sponses 20 h later. Fig. 1A illustrates the time course
of PLD activation by 1 WM fMLP and 100 WM ATP
in HL-60 cells electroporated with and without C3
exoenzyme1. Fig. 1B shows that both responses were
completely abolished by treatment with 1 Wg/ml C3
exoenzyme. Activation of PLD induced by 100 nM
PMA was also a¡ected by C3 exoenzyme treatment,
but the inhibition was only 32% (Fig. 1C).
The e¡ect of C3 exoenzyme on PLD activation in
di¡erentiated HL-60 cells was correlated with the
ADP-ribosylation of Rho proteins. To prove in situ
ADP-ribosylation of Rho proteins, HL-60 cells were
electroporated in the presence or absence of 1 Wg/ml
C3 exoenzyme, homogenized after 20 h and incu-
bated with C3 exoenzyme and [32P]NAD. Incorpora-
tion of [32P]ADP into Rho proteins was observed,
and was signi¢cantly lower in lysates from C3 exoen-
zyme-treated cells than in those from control cells,
indicating that Rho was ADP-ribosylated in situ by
the exoenzyme (Fig. 2). Since incorporation of
[32P]ADP into C3 exoenzyme-treated Rho proteins
was 16 þ 1% of control (n = 4), a large fraction of
Rho was ADP-ribosylated in the cells.
Fig. 1. Inhibition of PLD activation by treatment of HL-60
cells with C3 exoenzyme. Di¡erentiated HL-60 cells were elec-
troporated in the presence or absence of 1 Wg/ml C3 exoenzyme
and then incubated with medium containing [3H]myristate for
18^20 h as described in Section 2. (A,B) [3H]PtdBuOH forma-
tion was measured in the absence (E) or presence of 1 WM
fMLP (F) or 100 WM ATP (b). (C) [3H]PtdBuOH formation
was measured for 20 min in the presence or absence of 100 nM
PMA. Data are means þ S.D. for three experiments.
Fig. 2. ADP-ribosylation of Rho proteins in HL-60 cells treated
with C3 exoenzyme. Di¡erentiated HL-60 cells were electropo-
rated in the absence (lane 1) or presence (lane 2) of 1 Wg/ml C3
exoenzyme for 20 h and then lysed as described in Section 2.
The lysates were then incubated with 500 ng of C3 exoenzyme
and [32P]NAD and the labeling of Rho proteins analyzed by
SDS-PAGE and autoradiography. Rho protein (0.09 Wg) was
also subjected to ADP-ribosylation under the same conditions
(lane 3). The gels were analyzed using the NIH image program.
Similar results were obtained in three other experiments.
1 The greater e¡ect of ATP vs. fMLP in our experiments was
observed previously [50] and di¡ers from the results reported by
some other workers [28,57]. This could represent a clonal varia-
tion in the expression of the receptors for these agonists.
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We also investigated the e¡ect of C3 exoenzyme
on phosphoinositide levels in di¡erentiated HL-60
cells. This was because Rho family proteins have
been implicated in regulating the synthesis of
PtdInsP2 [33,34], a cofactor for PLD activation [7].
Di¡erentiated HL-60 cells were electroporated in the
presence or absence of 1 Wg/ml C3 exoenzyme and
incubated with [3H]inositol (2 WCi/ml) for 20 h before
determination of radioactive phosphoinositide levels.
In three independent experiments, we found no sig-
ni¢cant di¡erence in total incorporation of
[3H]inositol into phosphoinositides (175 000 þ 7 700
cpm vs. 163 000 þ 14 700 cpm). However, we ob-
served an increase of PtdInsP2 from 0.7 þ 0.2% of
total radioactive incorporation in control cells to
1.0 þ 0.2% in C3 exoenzyme-treated cells. The treat-
ment also caused an increase of PtdInsP from
1.4 þ 0.3% of total radioactive incorporation to
2.4 þ 0.2%. These results exclude the possibility that
C3 exoenzyme a¡ected PLD stimulation in di¡eren-
tiated HL-60 cells by inhibiting PtdInsP2 synthesis.
As has been extensively reported, PLD activity is
strongly enhanced when GTPQS is introduced into
permeabilized HL-60 cells, indicating the involve-
ment of a GTP-binding protein(s) in the regulation
of the enzyme. We observed that, in di¡erentiated
and L-escin-permeabilized HL-60 cells, this GTPQS-
stimulated PLD response was potentiated by ATP
(Fig. 3). Millimolar ATP was required to observe
this e¡ect since 10 WM and 100 WM ATP were inef-
fective (data not shown). It should also be noted
that, in the absence of guanine nucleotide, ATP in-
duced only a very modest accumulation of PdtBuOH
(see Fig. 6). Because a non-phosphorylating analog
of ATP, AMP-PNP, did not potentiate PtdBuOH
formation (Fig. 3), it appeared that ATP acted as a
phosphoryl group donor in the reaction.
We used L-escin-permeabilized HL-60 cells as an
experimental system to investigate the contribution
of Rho proteins to the GTPQS-dependent activation
of PLD and its potentiation by ATP. After electro-
poration of di¡erentiated HL-60 cells with or with-
out C3 exoenzyme (1 Wg/ml) and a 20 h recovery
period, cells were permeabilized by L-escin and
stimulated by GTPQS alone (1 WM^1 mM) or GTPQS
plus ATP (1 mM). While the basal PLD activity was
not signi¢cantly a¡ected by C3 exoenzyme treatment,
PLD activation induced by 1 mM GTPQS was inhib-
ited by 26 þ 4% in C3 exoenzyme-treated cells (Fig.
4). Similar inhibition (22^32%) was observed at other
GTPQS concentrations. The PLD response observed
in the presence of GTPQS plus ATP was also inhib-
ited by C3 exoenzyme (20 þ 4%). There was also in-
Fig. 3. E¡ects of GTPQS and ATP on PLD activity of perme-
abilized di¡erentiated HL-60 cells. Cells were labeled with
[3H]myristate and permeabilized with L-escin as described in
Section 2. They were then incubated for 20 min with the con-
centration of GTPQS shown in the presence (E) and absence (F)
of 1 mM ATP, and in the presence (a) and absence (O) of
1 mM AMP-PNP. PLD activity was assayed by [3H]PtdBuOH
formation. Data are means þ S.D. for four experiments.
Fig. 4. E¡ect of C3 exoenzyme pretreatment on the activation
of PLD by GTPQS in permeabilized di¡erentiated HL-60 cells.
Cells were treated with or without C3 exoenzyme, labeled with
[3H]myristate and permeabilized with L-escin as described in
Section 2. They were then incubated for 20 min with the con-
centrations of GTPQS shown and assayed for [3H]PtdBuOH for-
mation. F, treated cells ; a, untreated cells. Data are from three
experiments.
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hibition of the small accumulation of PdtBuOH
caused by ATP itself (data not shown). These data
thus indicated that Rho proteins made a minor con-
tribution to GTPQS-induced PLD activation in vi-
tro2.
To investigate the mechanism underlying the po-
tentiation by ATP of GTPQS-dependent PLD activa-
tion in di¡erentiated HL-60 cells, we examined the
e¡ect of di¡erent protein kinase inhibitors on this
response. No signi¢cant inhibition of the PLD acti-
vation induced by GTPQS plus ATP was observed
when di¡erentiated HL-60 cells were preincubated
10 min before their stimulation with the Ser/Thr kin-
ase inhibitor staurosporine at 5 WM (13.9 þ 0.9% and
15.5 þ 0.3% of total radioactive phospholipids, with-
out and with inhibitor, n = 3) or with the selective
protein kinase C inhibitor bisindolylmaleimide at
5 WM (13.8 þ 1.4% and 12.2 þ 1.1% of total radio-
active phospholipids, without and with inhibitor,
n = 3), although both inhibitors blocked the PMA-
induced PLD response at this concentration (data
not shown). Among the tyrosine kinase inhibitors
used (100 WM tyrphostin A, 50 WM erbstatin,
20 WM ST638, 20 WM lavendustin, 20 WM herbimycin
and 10^199 WM genistein), only genistein showed a
signi¢cant inhibition of the potentiation by ATP of
the GTPQS-dependent activation of PLD. However,
this inhibition was partial and was only observed
with high concentrations (100 WM) of genistein
(13.1 þ 0.4% and 9.6 þ 0.4% of total radioactive phos-
pholipids, without and with genistein). At this con-
centration, genistein is not considered to be a selec-
tive tyrosine kinase inhibitor and is capable of
inhibiting lipid kinases such as phosphatidylinositol
4-phosphate 5-kinase [30].
Since the use of protein kinase inhibitors did not
provide evidence for a role of protein phosphoryla-
tion in the potentiation by ATP of GTPQS-dependent
PLD activation, we tested the hypothesis that this
e¡ect could be a consequence of phospholipid phos-
phorylation. Considering that PtdInsP2 is an essen-
tial factor for PLD activation in vitro [7], synthesis
Fig. 6. Neomycin inhibition of the stimulation of PLD induced
by ATP in permeabilized HL-60 cells. Di¡erentiated HL-60
cells were labeled with [3H]myristate and permeabilized with
L-escin as described in Section 2. They were then incubated for
20 min with the concentrations of neomycin shown in the pres-
ence of 1 mM ATP alone (a), 100 WM GTPQS alone (E) and
ATP plus GTPQS (F). Data are from six experiments.
Fig. 5. Stimulation of PtdInsP and PtdInsP2 synthesis by ATP
in permeabilized HL-60 cells. Di¡erentiated HL-60 cells were
labeled with myo-[3H]inositol for 3 days. They were then per-
meabilized and incubated with 1 mM ATP in the presence or
absence of 100 WM GTPQS for 20 min. The synthesis of
[3H]PtdInsP and [3H]PtdInsP2 was measured by thin layer chro-
matography and liquid scintillation. Data are from four experi-
ments.
2 We also examined the e¡ects of Rho GDI and Rho anti-
bodies in cells permeabilized by L-escin. However, no changes
were observed, perhaps because e¡ective intracellular concentra-
tions of these reagents were not achieved.
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of PtdInsP2 in the presence of 1 mM ATP was ex-
amined in permeabilized HL-60 cells. The e¡ect of
1 mM ATP on PtdInsP and PtdInsP2 levels was in-
vestigated in [3H]inositol-labeled HL-60 cells. Di¡er-
entiated cells were labeled for 3 days with
[3H]inositol, permeabilized by L-escin and then
stimulated by ATP or ATP plus GTPQS for 20 min
under the same conditions used for the PLD assay.
After treatment, lipids were extracted and
[3H]PtdInsP and [3H]PtdInsP2 were quanti¢ed. ATP
(1 mM) caused an increase in the levels of both
[3H]PtdInsP and [3H]PtdInsP2 while GTPQS did not
(Fig. 5). When [3H]inositol-labeled cells were treated
with both GTPQS (100 WM) and ATP (1 mM), the
increases in the labeled inositol phospholipids were
similar to those induced by ATP alone (Fig. 5). To
further demonstrate that ATP could contribute to
PLD activation by inducing PtdInsP2 synthesis in
di¡erentiated HL-60 cells, we also used neomycin,
a cationic aminoglycoside antibiotic that exhibits
high binding a⁄nity for inositol phospholipids, espe-
cially PtdInsP2 [31,32]. Fig. 6 shows that incubation
of intact di¡erentiated HL-60 cells in the presence of
neomycin for 10 min did not signi¢cantly a¡ect
GTPQS-dependent PLD activation, but prevented
the potentiation by ATP of the GTPQS e¡ect. Indeed,
potentiation by ATP was completely abolished by
600 WM neomycin. Neomycin also inhibited the small
PLD activation caused by ATP itself.
4. Discussion
Identi¢cation of Rho as regulatory factor of PLD
was ¢rst indicated by the observation that Rho GDI,
which extracts Rho proteins from membranes, pre-
vented GTPQS-dependent activation of PLD in HL-
60 [18] and rat liver [10] membranes. PLD activation
was restored by the addition of RhoA [10,33]. Siddi-
qi et al. [9] showed that not only RhoA but also
Rac1 and Cdc42Hs induced PLD activation in HL-
60 cell membranes. The e¡ect of RhoA has been
con¢rmed by Martin et al. [34], but these workers
were unable to see an e¡ect of Rho GDI and con-
cluded that the stimulatory e¡ect of GTPQS on PLD
in HL-60 cell membranes was mediated by endoge-
nous Arf [34].
The present study employed C. botulinum C3
exoenzyme to determine the physiological role of
Rho proteins in receptor-mediated regulation of
PLD in intact di¡erentiated HL-60 cells. This exoen-
zyme has been demonstrated to ADP-ribosylate
RhoA 100-fold more e⁄ciently than Rac1 and 400-
fold more e⁄ciently than Cdc42Hs [15] and to selec-
tively block Rho-mediated changes in intact cells
[35^38]. Thus it is reasonable to ascribe its e¡ects
as due to inactivation of Rho in the present study.
The exoenzyme inactivates Rho proteins in vitro but
enters intact cells poorly [39]. We found that cell
electroporation allowed the introduction of C3
exoenzyme into the cells and the ADP-ribosylation
of 84% of the endogenous Rho (Fig. 2). The electro-
poration alone did not alter the response of the cells
to agonists (Fig. 2). This made it possible to study
the role of Rho proteins in an intact cellular system.
Our results show that fMLP- and ATP-stimulated
PLD activity was completely suppressed in C3 exoen-
zyme-treated cells (Fig. 1), demonstrating a key role
for Rho proteins. The mechanism(s) by which these
proteins activate PLD in intact cells is unclear, but
GTPQS-activated forms of recombinant RhoA, Rac1
and Cdc42Hs have been shown to activate homoge-
neous preparations of the hPLD1 and rPLD1 iso-
zymes of PLD in vitro [40^42]. Thus direct interac-
tion of these Rho family proteins with these PLD
isozymes produces a large increase in PLD activity
[40^42]. It has also been shown that treatment of
Swiss 3T3 cells with agonists in vivo or GTPQS in
vitro induces membrane translocation of Rho family
proteins [43]. Therefore it is possible that agonists
could induce the activation and translocation of
these proteins to cellular sites enriched in PLD, lead-
ing to activation of the enzyme.
Another possibility is that the action of RhoA
proteins on PLD is indirect. Jakobs and associates
[44] have proposed that C3 exoenzyme and Toxin B
from C. di⁄cile inhibit PLD activation through a
reduction in PtdInsP2 synthesis. As noted above,
this lipid is essential for stimulation of PLD in vitro
[7,45,46] and there is evidence that Rho family pro-
teins play a role in its synthesis by PtdInsP 5-kinase
[47,48]. Furthermore, as shown for HL-60 cells in the
present study, the addition of MgATP to perme-
abilized HEK cells enhanced the e¡ect of GTPQS
on PLD activity [44]. This was associated with an
increase in PtdInsP2 and was blocked by neomycin
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[44]. Toxin B produced a partial inhibition of PLD
activity which could be reversed by addition of
PtdInsP2 to the permeabilized cells.
Despite the strong evidence that PtdInsP2 can con-
trol PLD activity in vitro and in permeabilized cells
[7,41,44^46,49], it is less clear that it can do so in
vivo. For example, although treatment of HEK cells
with 50 Wg/ml Toxin B for 24 h produced a 40%
reduction of PtdInsP2 [44] it was not demonstrated
that this was responsible for the virtual abolition of
agonist activation of PLD in these cells [26]. In the
present study, we failed to see decreases in PtdInsP
or Ptd InsP2 in cells treated with C3 exoenzyme
under the same conditions that PLD activity was
measured. In fact, the reagent produced 40^70% in-
creases in these lipids. We did not determine the
basis for these increases, but they clearly exclude a
decrease in PtdInsP2 as a mechanism for the e¡ect of
C3 exoenzyme on PLD activity in our experiments.
Despite the abolition of agonist-induced PLD ac-
tivation in intact HL-60 cells by C3 exoenzyme, the
activation of PLD by GTPQS in vitro was only partly
decreased. One explanation is that the 84% inactiva-
tion of total cellular induced Rho by C3 exoenzyme
was still insu⁄cient to completely block the action of
this G protein in the L-escin-permeabilized cells. This
possibility is supported by the ¢nding that complete
glucosylation of Rho proteins induced by Toxin B
caused abolition of the PLD response to GTPQS in
HL-60 lysates [19], and that C3 exoenzyme produced
a 65% inhibition of the e¡ect in HL-60 cell mem-
branes [24]. Likewise, Schmidt et al. [26,44] observed
60^80% inhibition of the PLD response by C3 exoen-
zyme and Toxin B, respectively, in digitonin-permea-
bilized HEK cells, and a large inhibition has been
reported in basophilic leukemia cells [22]. Summariz-
ing all these reports, Rho appears to play a signi¢-
cant role in the e¡ect of GTPQS on PLD in perme-
abilized cells or cell lysates.
In agreement with other studies with Clostridial
toxins [10,22,26], C3 exoenzyme produced less inhib-
ition of the PLD activation induced by PMA com-
pared with that caused by agonists. This suggests
that PKC-mediated activation of PLD is less depen-
dent on Rho proteins. There is evidence that conven-
tional PKC isozymes can directly activate certain
PLD isozymes [11,40,41] and this could explain the
Rho-independent activation of PLD by PMA. Con-
cerning the Rho-dependent mechanism, this could
involve Rho proteins as downstream mediators of
certain PKC actions, or could arise from the demon-
strated ability of RhoA and PKCK to interact syn-
ergistically to activate PLD [11,17,49].
The incomplete inactivation of the GTPQS-induced
PLD in vitro response by C3 exoenzyme observed in
the present and other [24,26] studies raises the possi-
bility that another small GTP-binding protein in in-
volved. A likely candidate is a member(s) of the Arf
family because of their known stimulatory e¡ects on
PLD in vitro [7^9,11]. However, our previous e¡orts
to prove this in permeabilized cells using brefeldin A,
an inhibitor of Arf activation, [50] were unsuccessful.
Furthermore, when arfaptin 1, an Arf binding pro-
tein [51] and inhibitor of Arf action of PLD [58], was
introduced in HL-60 cells by electroporation or
added to the permeabilized cells, no inhibition of
GTPQS activation of PLD was observed (I. Guille-
main, J.H. Exton, unpublished observations). Ex-
pression of constitutively active L71 Arf3 in COS7
cells was also unable to activate co-expressed rPLD1
[52]. Thus it has been di⁄cult to demonstrate Arf
regulation of PLD in an intact or permeabilized
cell setting, perhaps because of the presence of arfap-
tin [51] or other inhibitory proteins. It is possible that
the regulation of PLD by Arfs in intact cells may be
con¢ned to the Golgi or plasma membrane [53,54].
This question needs further work since a recent re-
port has implicated Arf in the regulation of PLD by
fMLP in streptolysin O-permeabilized neutrophils
[55].
The failure of any Ser/Thr protein kinase inhibitor
to in£uence the potentiation by ATP of the stimula-
tion of PLD by GTPQS in the permeabilized cells was
somewhat surprising since synergistic interaction be-
tween conventional PKC isozymes and Rho or Arf in
the regulation of PLD has been well demonstrated
[11,33,40,49]. The presence of PKC in the perme-
abilized cells was demonstrated by the stimulatory
e¡ect of PMA, which was blocked by PKC inhibitors
(data not shown). On the other hand, the action of
ATP was attributable to an increase in PtdInsP2
since the nucleotide induced a 3-fold increase in
this lipid (Fig. 5) and its action on PLD was blocked
by neomycin, as observed in permeabilized neutro-
phils [56]. An increase in PtdInsP2 with ATP has also
been observed in other studies with HL-60 cell mem-
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branes [49] and permeabilized HEK and U937 cells
[44,46]. Interestingly, ATP alone did not increase
PLD activity and addition of GTPQS was necessary
to see its e¡ect.
In summary, the present results point to a major
role for Rho proteins in the stimulation of PLD by
fMLP and ATP in HL-60 cells, but only a partial
role in the e¡ect of PMA. However, the mechanism
of action of Rho proteins on PLD activity in the
intact cells is still not de¢ned and the role, if any,
of Arf in the mediation of agonist stimulation of
PLD in these cells remains unclear. Thus consider-
able further work is required to de¢ne exactly how
PLD is regulated by Rho and Arf in intact cells.
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